Example of memo - Magazine of European Medical Oncology format
Recent searches

Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format Example of memo - Magazine of European Medical Oncology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

memo - Magazine of European Medical Oncology — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Hematology #88 of 123 up up by 14 ranks
Oncology #247 of 340 up up by 17 ranks
journal-quality-icon Journal quality:
Medium
calendar-icon Last 4 years overview: 258 Published Papers | 439 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 20/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access

Springer

Quality:  
High
CiteRatio: 4.6
SJR: 1.06
SNIP: 1.301
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.3
SJR: 1.037
SNIP: 0.989
open access Open Access
recommended Recommended

Elsevier

Quality:  
High
CiteRatio: 12.1
SJR: 2.67
SNIP: 2.494

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.7

13% from 2019

CiteRatio for memo - Magazine of European Medical Oncology from 2016 - 2020
Year Value
2020 1.7
2019 1.5
2018 0.9
2017 0.7
2016 0.5
graph view Graph view
table view Table view

0.369

13% from 2019

SJR for memo - Magazine of European Medical Oncology from 2016 - 2020
Year Value
2020 0.369
2019 0.328
2018 0.243
2017 0.21
2016 0.123
graph view Graph view
table view Table view

0.247

13% from 2019

SNIP for memo - Magazine of European Medical Oncology from 2016 - 2020
Year Value
2020 0.247
2019 0.218
2018 0.17
2017 0.137
2016 0.081
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 13% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 13% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 13% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

memo - Magazine of European Medical Oncology

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

memo - Magazine of European Medical Oncology

The focus of the journal "magazine of european medical oncology ? memo" is to offer a professional review on current research and development in the field of hematology and oncology relevant for daily practice. Therefore, memo includes editorials and comments, peer-reviewed or...... Read More

Oncology

Hematology

Medicine

i
Last updated on
20 Jul 2020
i
ISSN
1865-5041
i
Impact Factor
Low - 0.064
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SPBASIC
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1007/S12254-018-0389-X
Pitfalls in the radiological response assessment of immunotherapy
Lucian Beer1, Maximilian Hochmair, Helmut Prosch1

Abstract:

Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial ... Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization criteria. Consequently, adaptions of these criteria have been released such as the immune-related RECIST and immune RECIST, which account for the specialities of immunotherapies. Immunotherapies can cause a distinct set of adverse events such as pneumonitis, colitis, and hypophysitis. In addition, atypical treatment response patterns termed pseudoprogression have been observed. Thereby, new or enlarging lesions appear after treatment start and mimic tumor progression, which is followed by an eventual decrease in total tumor burden. In this review article we will describe pitfalls in the radiological response assessment of immunotherapies, focusing on pseudoprogression and imaging appearances of common immune-related adverse events. read more read less

Topics:

Response Evaluation Criteria in Solid Tumors (61%)61% related to the paper, Immunotherapy (59%)59% related to the paper, Pseudoprogression (54%)54% related to the paper
View PDF
60 Citations
Journal Article DOI: 10.1007/S12254-010-0219-2
Analysis of exhaled breath for screening of lung cancer patients

Abstract:

The fast development of analytical techniques in the field of gas analysis can be compared to that of computers during the last two decades. Not only speed but also sensitivity of analysis has been greatly improved, sometimes by a factor of 100 or more. This technological development has fostered the analysis of exhaled breat... The fast development of analytical techniques in the field of gas analysis can be compared to that of computers during the last two decades. Not only speed but also sensitivity of analysis has been greatly improved, sometimes by a factor of 100 or more. This technological development has fostered the analysis of exhaled breath. Since this can be done in real-time, very fast biological processes can be monitored. Also simulation and modelling of haemodynamics and lung mechanics become possible. During the next decade we will see miniaturized equipment (of the size of a cigarette box) appear. Here we review and illustrate the rich diversity of compounds observed in exhaled breath with a particular focus on lung cancer patients. Each of the many volatile compounds has its own particular biochemical background, and cell types with different genetic background have been shown to have a different pattern of released and consumed volatile compounds. Nevertheless we still lack an understanding, if and how genetic alterations, which are seen as the underlying cause of the transformation process, control the VOC phenotype observed in patients or cancer cell lines. The concentration pattern of volatile compounds in exhaled breath may be used in the future for phenotyping individuals in large-scale screening approaches. Also changes in VOC patterns may provide disease-relevant information (e.g. on the activity of metabolizing enzymes). Future applications will also include the follow-up of exogenous compounds which are ingested or inhaled as drugs, food components or components in cigarette smoke and metabolic products of these compounds. read more read less
45 Citations
open accessOpen access Journal Article DOI: 10.1007/S12254-017-0341-5
New diagnostic tools for breast cancer.
Pascal A. T. Baltzer1, Panagiotis Kapetas1, Maria Adele Marino1, Paola Clauser1

Abstract:

Imaging plays a major role in the diagnosis, treatment, and follow-up of breast cancer. Findings that require further assessment will be detected both at screening and curative mammography. Most findings that are further worked up tend to yield benign diagnoses. Consequently, there is an ongoing search for new tools to reduce... Imaging plays a major role in the diagnosis, treatment, and follow-up of breast cancer. Findings that require further assessment will be detected both at screening and curative mammography. Most findings that are further worked up tend to yield benign diagnoses. Consequently, there is an ongoing search for new tools to reduce recalls and unnecessary biopsies while maintaining or improving cancer detection rates. The clinically most promising methods in this respect are described and discussed in this review. read more read less

Topics:

Mammography (57%)57% related to the paper, Breast cancer (56%)56% related to the paper
View PDF
37 Citations
open accessOpen access Journal Article DOI: 10.1007/S12254-016-0292-2
PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.
Georg Hutarew1

Abstract:

Tumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1) Checkpoint inhibitors (ICI) provide encouraging therapeutic results in non-small cell lung cancers (NSCLC) and may soon be used in 2nd or 1st line therapy Cu... Tumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1) Checkpoint inhibitors (ICI) provide encouraging therapeutic results in non-small cell lung cancers (NSCLC) and may soon be used in 2nd or 1st line therapy Currently PD-L1 immunohistochemistry (IHC) expression assessed on tumour cells is used as a predictive biomarker, since better patient outcomes are often, but not always associated with increased tumour cell PD-L1 IHC expression However pre-analytical variables, different anti-PD-L1 clones used on different staining platforms, different specimens types, as well as intra- and interobserver variability influence the results We will only understand PD-L1 expression on tumour cells if we accept that PD-L1 is an inducible pathophysiological factor with variable levels of PD-L1 expression depending on the immunological status Should we test PD-L1 during initial diagnostic work up before, or at the point when immune checkpoint therapy is considered? Taking all arguments into account the value of PD-L1 as a predictive biomarker is questionable Other predictive biomarkers such as high mutation burden, mRNA expression, neo-antigens and the diversity of tumour antigen-specific T cells should be evaluated in the future Here we review results presented in 30 journal articles and three reviews covering this topic in the last 3 years read more read less

Topics:

Immune checkpoint (54%)54% related to the paper, Biomarker (medicine) (52%)52% related to the paper, Germline mutation (50%)50% related to the paper
View PDF
36 Citations
open accessOpen access Journal Article DOI: 10.1007/S12254-021-00680-X
WHO classification of tumors of the nervous system: preview of the upcoming 5th edition

Abstract:

Identification of the underlying genetic and epigenetic alterations in an increasing number of tumors of the nervous system is contributing to a more clinically relevant classification. In the following article, the 7 cIMPACT-NOW publications, which adumbrate the upcoming 5th edition of the WHO Classification of Tumours of th... Identification of the underlying genetic and epigenetic alterations in an increasing number of tumors of the nervous system is contributing to a more clinically relevant classification. In the following article, the 7 cIMPACT-NOW publications, which adumbrate the upcoming 5th edition of the WHO Classification of Tumours of the Central Nervous Sytem are summarized. read more read less
View PDF
35 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for memo - Magazine of European Medical Oncology.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

memo - Magazine of European Medical Oncology format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write memo - Magazine of European Medical Oncology in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the memo - Magazine of European Medical Oncology guidelines and auto format it.

2. Do you follow the memo - Magazine of European Medical Oncology guidelines?

Yes, the template is compliant with the memo - Magazine of European Medical Oncology guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in memo - Magazine of European Medical Oncology?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the memo - Magazine of European Medical Oncology citation style.

4. Can I use the memo - Magazine of European Medical Oncology templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for memo - Magazine of European Medical Oncology.

5. Can I use a manuscript in memo - Magazine of European Medical Oncology that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper memo - Magazine of European Medical Oncology that you can download at the end.

6. How long does it usually take you to format my papers in memo - Magazine of European Medical Oncology?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in memo - Magazine of European Medical Oncology.

7. Where can I find the template for the memo - Magazine of European Medical Oncology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per memo - Magazine of European Medical Oncology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the memo - Magazine of European Medical Oncology's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. memo - Magazine of European Medical Oncology an online tool or is there a desktop version?

SciSpace's memo - Magazine of European Medical Oncology is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like memo - Magazine of European Medical Oncology?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like memo - Magazine of European Medical Oncology?”

11. What is the output that I would get after using memo - Magazine of European Medical Oncology?

After writing your paper autoformatting in memo - Magazine of European Medical Oncology, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is memo - Magazine of European Medical Oncology's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for memo - Magazine of European Medical Oncology?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for memo - Magazine of European Medical Oncology. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In memo - Magazine of European Medical Oncology?

The 5 most common citation types in order of usage for memo - Magazine of European Medical Oncology are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the memo - Magazine of European Medical Oncology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per memo - Magazine of European Medical Oncology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download memo - Magazine of European Medical Oncology in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in memo - Magazine of European Medical Oncology Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to memo - Magazine of European Medical Oncology formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template